- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-NF2L2/ Nrf2/ NFE2L2 monoclonal antibody
Anti-NF2L2/ Nrf2/ NFE2L2 antibody for FACS & in-vivo assay
Go to Nrf2/NFE2L2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-T88505-Ab-1/ GM-Tg-hg-T88505-Ab-2 | Anti-Human Nrf2/NFE2L2 monoclonal antibody | Human |
| GM-Tg-rg-T88505-Ab-1/ GM-Tg-rg-T88505-Ab-2 | Anti-Rat Nrf2/NFE2L2 monoclonal antibody | Rat |
| GM-Tg-mg-T88505-Ab-1/ GM-Tg-mg-T88505-Ab-2 | Anti-Mouse Nrf2/NFE2L2 monoclonal antibody | Mouse |
| GM-Tg-cynog-T88505-Ab-1/ GM-Tg-cynog-T88505-Ab-2 | Anti-Cynomolgus/ Rhesus macaque Nrf2/NFE2L2 monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-T88505-Ab-1/ GM-Tg-felg-T88505-Ab-2 | Anti-Feline Nrf2/NFE2L2 monoclonal antibody | Feline |
| GM-Tg-cang-T88505-Ab-1/ GM-Tg-cang-T88505-Ab-2 | Anti-Canine Nrf2/NFE2L2 monoclonal antibody | Canine |
| GM-Tg-bovg-T88505-Ab-1/ GM-Tg-bovg-T88505-Ab-2 | Anti-Bovine Nrf2/NFE2L2 monoclonal antibody | Bovine |
| GM-Tg-equg-T88505-Ab-1/ GM-Tg-equg-T88505-Ab-2 | Anti-Equine Nrf2/NFE2L2 monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-T88505-Ab-1/ GM-Tg-hg-T88505-Ab-2; GM-Tg-rg-T88505-Ab-1/ GM-Tg-rg-T88505-Ab-2; GM-Tg-mg-T88505-Ab-1/ GM-Tg-mg-T88505-Ab-2; GM-Tg-cynog-T88505-Ab-1/ GM-Tg-cynog-T88505-Ab-2; GM-Tg-felg-T88505-Ab-1/ GM-Tg-felg-T88505-Ab-2; GM-Tg-cang-T88505-Ab-1/ GM-Tg-cang-T88505-Ab-2; GM-Tg-bovg-T88505-Ab-1/ GM-Tg-bovg-T88505-Ab-2; GM-Tg-equg-T88505-Ab-1/ GM-Tg-equg-T88505-Ab-2 |
| Products Name | Anti-Nrf2/NFE2L2 monoclonal antibody |
| Format | mab |
| Target Name | Nrf2 |
| Protein Sub-location | Transmembrane Protein |
| Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-Nrf2 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation | Lyophilized from sterile PBS, PH 7.4 |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | Products Developing | Multi-species NF2L2/ Nrf2/ NFE2L2 VLP (virus-like particle) (Products Developing) |
| ORF Viral Vector | vGMLV000194 | human NFE2L2 Lentivirus particle |
| ORF Viral Vector | vGMLV000643 | human NFE2L2 Lentivirus particle |
| ORF Viral Vector | pGMLV000569 | human nrf2 Lentivirus plasmid |
| ORF Viral Vector | pGMLV000194 | human NFE2L2 Lentivirus plasmid |
| ORF Viral Vector | vGMLV000569 | human nrf2 Lentivirus particle |
| ORF Viral Vector | pGMLV000643 | human NFE2L2 Lentivirus plasmid |
| ORF Viral Vector | vGMLV000762 | human NFE2L2 Lentivirus particle |
| ORF Viral Vector | pGMLV000762 | human NFE2L2 Lentivirus plasmid |
| ORF Viral Vector | pGMLV000784 | house mouse Nfe2l2 Lentivirus plasmid |
| ORF Viral Vector | pGMAAV000087 | rat Nfe2l2 AAV plasmid |
| ORF Viral Vector | vGMLV000784 | house mouse Nfe2l2 Lentivirus particle |
| ORF Viral Vector | vGMAAV000087 | rat Nfe2l2 AAV particle |
Target information
| Target ID | GM-T88505 |
| Target Name | Nrf2 |
| Gene ID | 4780,18024,83619,707606,478813,101098812,497024,100066816 |
| Gene Symbol and Synonyms | HEBP1,IMDDHH,NFE2L2,Nrf-2,NRF2 |
| Uniprot Accession | Q16236,O54968,Q5NUA6 |
| Uniprot Entry Name | NF2L2_HUMAN,NF2L2_RAT,NF2L2_BOVIN |
| Protein Sub-location | Transmembrane Protein |
| Category | Therapeutics Target |
| Disease | Cancer |
| Gene Ensembl | ENSG00000116044 |
| Target Classification | Pathway, Tumor-associated antigen (TAA) |
The target: Nrf2, gene name: NFE2L2, also named as HEBP1, IMDDHH, NRF2. This gene encodes a transcription factor which is a member of a small family of basic leucine zipper (bZIP) proteins. The encoded transcription factor regulates genes which contain antioxidant response elements (ARE) in their promoters; many of these genes encode proteins involved in response to injury and inflammation which includes the production of free radicals. Multiple transcript variants encoding different isoforms have been characterized for this gene. [provided by RefSeq, Sep 2015].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
